We are happy to share that Genialis, one of our portfolio companies, has entered into a collaboration with Tempus AI, a leader in AI-driven precision medicine. This multi-year partnership leverages Tempus’ extensive multimodal dataset to develop and validate Genialis advanced RNA-based biomarker algorithms (Genialis TM Supermodel) aimed at revolutionizing cancer diagnosis and treatment.
As part of the collaboration, Genialis gains access to Tempus’ analytics platform, Lens, which facilitates the validation and deployment of its clinical algorithms. This access significantly accelerates the path to market for innovations like Genialis™krasID, a first-of-its-kind algorithm that identifies patients most likely to benefit from KRAS-targeted therapies. Independently validated with Tempus data, krasID empowers clinicians and biopharma to tailor cancer treatments across various cancer types and driver mutations.
This partnership highlights Genialis’ commitment to transforming cancer care by addressing critical gaps in biomarker accuracy and predictive power. Together, these companies are driving a future where RNA-based biomarkers enable personalized treatment decisions, enhancing patient outcomes worldwide.
Discover more here.